Clinical trials: Concentration
Attention-deficit/Hyperactivity Disorder
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
The purpose of this study is to determine effectiveness of Vyvanse compared to Concerta in adolescents with Attention-deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT01552902
- Testing
- Lisdexamfetamine dimesylate, Methylphenidate Hydrochloride
- Where
- 95 sites in United States, Canada and 3 more
- Volunteers
- 549 people
- Sponsor
- Shire
Autism Spectrum Disorder
VR for Joint Attention Support in ASD
The overall objective of this study is to determine the effectiveness of the Floreo VR Joint Attention Module in improving social communication skills in children with ASD.
- Trial name
- NCT04016701
- Testing
- Floreo Joint Attention Module, Regularly Scheduled Therapy
- Where
- United States
- Sponsor
- Floreo, Inc.
Pharmacokinetics of Mirabegron, Healthy Subjects
To Compare Blood and Urine Concentrations of Mirabegron (YM178) in Healthy Poor or Extensive Metabolizers for CYP2D6 and to Assess the Effect of Mirabegron on the Metabolism of Metoprolol
The study aims to compare blood and urine concentrations of mirabegron (YM178) in healthy poor or extensive metabolizers for CYP2D6 and to evaluate if blood levels of metoprolol change whilst being dosed at the same time with…
- Trial name
- NCT01478490
- Testing
- mirabegron, metoprolol
- Where
- Netherlands
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
ADHD
Amphetamine Extended Release Tablets and Driving Performance in Subjects With Attention Deficit/Hyperactivity Disorder (ADHD)
The purpose of this study is to assess the effect on driving performance of a single dose of amphetamine extended-release tablets (20 mg/tablet) compared with placebo at 45 minutes and 10 hours post-dose in young adults with ADHD.
- Trial name
- NCT04027361
- Testing
- Amphetamine Extended Release (ER) Tablet 20 mg
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Tris Pharma, Inc.
Hypertension
Effects of Adalat LA and Coracten on Drug Levels, Blood Pressure, and Heart Rate in Fed Patients With Hypertension
This study compares the effect of Adalat LA to Coracten on drug levels as well as changes in blood pressure and heart rate in fed hypertensive subjects.
- Trial name
- NCT00672113
- Testing
- Adalat (Nifedipine, BAYA1040), Coracten
- Where
- United Kingdom
- Volunteers
- 43 people
- Sponsor
- Bayer
Skin Infections, Bacterial
Retapamulin Microdialysis Feasibility Study
This feasibility study will allow for the determination of the in vivo recovery and time of dialysis to optimize a future thorough microdialysis study.
- Trial name
- NCT01812382
- Testing
- Retapamulin Microdialysis
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Patients on Stable Chronic Maintenance Dialysis Who Are Receiving Hemodialysis Therapy, Pharmacodynamics of ASP7991
Examination of Plasma Concentrations and Safety in Chronic Kidney Disease Patients Undergoing Hemodialysis
This study is to assess the safety, tolerability, plasma concentration and pharmacodynamics of ASP7991 after oral administration to patients with chronic kidney disease undergoing hemodialysis.
- Conditions
- Patients on Stable Chronic Maintenance Dialysis Who Are Receiving Hemodialysis Therapy, Pharmacodynamics of ASP7991, Pharmacokinetics of ASP7991
- Trial name
- NCT01872026
- Testing
- ASP7991
- Where
- Japan
- Volunteers
- 14 people
- Sponsor
- Astellas Pharma Inc
Healthy
Study Of The PF-04958242 Blood Concentrations Of A Capsule Formulation Of PF-04958242 Compared To A Solution Formulation
This study will assess the relative bioavailability of a capsule formulation of PF-04958242, relative to a oral solution formulation of PF-04958242 in healthy adult subjects.
- Trial name
- NCT01646840
- Testing
- PF-04958242 capsule, PF-04958242 oral solution
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Biogen
Infections
Assess the Plasma, Epithelial Lining, and Alveolar Macrophage Concentrations of Intravenous Meropenem-Pralubactam (Meropenem/FL058) in China Healthy Adult Participants
The goal of this clinical trial is to evaluate the Epithelial Lining Fluid concentrations and permeability of Intravenous Meropenem-Pralubactam(Meropenem/FL058) in China Healthy Adult Participants.
- Trial name
- NCT07124468
- Testing
- Meropenem-Pralubactam
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Contraception
E4/DRSP Single and Multiple Dose PK and Early QT Study
This study is conducted to evaluate the effect of single and multiple therapeutic and supratherapeutic oral doses of E4/DRSP combinations on PK parameters, safety, tolerability and on cardiac repolarization, as detected by QT…
- Trial name
- NCT02874248
- Testing
- 15 mg E4/3 mg DRSP, 30 mg E4/6 mg DRSP, 60 mg E4/12 mg DRSP
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Estetra
Attention Deficit Hyperactivity Disorder (ADHD)
Dose-Optimization Study Evaluating the Efficacy, Safety and Tolerability of Vyvanse (Lisdexamfetamine Dimesylate) in Children Aged 6-12 Diagnosed With ADHD
Assess the efficacy \& tolerability of Vyvanse when children aged 6-12 years diagnosed with ADHD are dosed to optimal effect.
- Trial name
- NCT00500071
- Testing
- Vyvanse (lisdexamfetamine dimesylate)
- Where
- 46 sites in United States
- Volunteers
- 318 people
- Sponsor
- Shire
Attention Deficit Disorder With Hyperactivity
CONCERTA (OROS Methylphenidate Hydrochloride) for the Treatment of Attention Deficit Hyperactivity Disorder in Adults
The purpose of this pilot study is to evaluate the safety, tolerability and potential effectiveness of CONCERTA® (methylphenidate hydrochloride extended-release tablets), a central nervous system (CNS) stimulant for the…
- Trial name
- NCT00246207
- Testing
- CONCERTA (OROS methylphenidate hydrochloride)
- Volunteers
- 32 people
- Sponsor
- Janssen-Ortho Inc., Canada
To Determine Brain Target Occupancy of BPN14770
A Phase 1, Open-Label, PET Study of T2310 & BPN14770
This is a sponsor initiated, single site, first-in-human study of an investigational imaging agent for quantifying the topographically specific concentrations of the phosphodiesterase enzyme Type 4D (PDE4D) with positron emission…
- Trial name
- NCT04044781
- Testing
- BPN14770, T2310
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Tetra Discovery Partners
Attention Deficit Hyperactivity Disorder
Efficacy and Safety of NS2359 in Adults With Attention Deficit Hyperactivity Disorder
The purpose of the study is to investigate if NS2359 is effective in the treatment of ADHD in adult patients.
- Trial name
- NCT00467428
- Testing
- NS2359
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- NeuroSearch A/S
Muscular Dystrophies
A Study to Assess the Feasibility of Non-invasive Dried Blood Sampling
This is a Phase I, open-label, single-dose, 1-period study to compare EDG-5506 concentrations measured from venous and capillary blood sampling in healthy adult subjects.
- Trial name
- NCT05492734
- Testing
- EDG-5506
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Edgewise Therapeutics, Inc.
Attention-Deficit/Hyperactivity Disorder
Open-label Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD and Mood Symptoms
Open label, flexible dose, decentralized clinical trial evaluating the efficacy and safety of SPN-812 in adults with ADHD and mood symptoms.
- Trial name
- NCT06185985
- Testing
- SPN-812
- Where
- United States
- Volunteers
- 161 people, healthy volunteers welcome
- Sponsor
- Supernus Pharmaceuticals, Inc.
Attention Deficit Disorder With Hyperactivity
Safety and Efficacy Study of Centanafadine Sustained-Release (CTN SR) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
This was a Phase 2b, randomized, double-blind, multicenter, 2-period, 2-treatment, crossover study to evaluate safety and efficacy of CTN SR compared with placebo in adults with ADHD.
- Trial name
- NCT02547428
- Testing
- CTN SR
- Where
- 4 sites in United States
- Volunteers
- 85 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Obesity
A Research Study Investigating Safety and Concentration in the Blood After One Dose Tablet of the New Medicine Monlunabant in Healthy Weight Japanese and Caucasian Men
The study is testing a new study drug in healthy normal weight Japanese and Caucasian participants after a single dose. The aim of this study is to see if the new medicine is safe and how it works in the participants body.
- Trial name
- NCT06542536
- Testing
- Monlunabant
- Where
- United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Autistic Disorder, Attention Deficit Disorder With Hyperactivity
Atomoxetine Versus Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents With Autism Spectrum Disorder
The purpose of this study is to determine whether atomoxetine is effective in reducing ADHD (Attention Deficit/Hyperactivity Disorder) symptoms in children and adolescents with ASD (Autism Spectrum Disorder).
- Trial name
- NCT00380692
- Testing
- Atomoxetine
- Where
- 8 sites in Netherlands
- Volunteers
- 97 people
- Sponsor
- Eli Lilly and Company
Attention-Deficit/Hyperactivity Disorder (ADHD)
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD
This study will evaluate the efficacy and safety of SPN-812 (Viloxazine extended-release capsules; 200-600 mg) in adults 18-65 years of age with Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT04016779
- Testing
- SPN-812
- Where
- 37 sites in United States
- Volunteers
- 374 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.